- At the upcoming American College of Rheumatology Congress in Boston, MA, Novartis (NVS +0.6%) will present Phase 3 data for secukinumab for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
- Four oral presentations are scheduled for November 16 and 18. Four posters will be presented on November 16.
- Secukinumab is a human monoclonal antibody that inhibits IL-17A. It is the first such inhibitor to demonstrate positive Phase 3 results in PsA and AS.
- Previously: More positive results for secukinumab